Pfizer: Innovation at the Lowest Cost
Executive Summary
Pfizer's economic figuring goes something like this: an internally discovered drug, or one licensed for relatively little money at an early stage of development, can nonetheless be considerably less profitable than one in-licensed when it is nearly ready for NDA filing, even if the drug costs a small fortune in cash and quids.
You may also be interested in...
Ironwood Pharmaceuticals: Independent for the Long Haul
Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.
Ironwood Pharmaceuticals: Independent for the Long Haul
Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.
Canary in the Coalmine: Pfizer R&D
In an interview, Pfizer's head of R&D, John LaMattina, discusses R&D's position as the part of the company most vulnerable to cuts in response to weakening sales. Among other issues, LaMattina discusses Pfizer's increasing interest in large molecules, specialist markets and combination products, and the role external research will play in filling a pipeline facing significant near-term generic pressures. He also details Pfizer's advantages of scale, particularly in developing portfolios of products in individual disease areas for sale to major customers interested in large discounted, disease-managed product packages.